Category: ALK Positive News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
ALK Positive, Inc. Sponsors Real-World Registry that Confirms the Success of Modern ALK Therapy, and the Contribution of ALK Positive’s Collaborative Clinical Trial Efforts.
The ALK Life Study, a global, patient-led observational registry and longitudinal survey created by ALK Positive, Inc. for patients with ALK-positive (ALK+) non-small cell lung cancer, has published its findings in JCO Global Oncology. The study tracks the natural history of the disease, diagnostic timelines, and real-world treatment patterns over time. Led by patient advocate…
-
Advancing Research Together: Honored to Be Named CTI Cares’ Q3 Charity of the Quarter
Progress against ALK-positive cancer has always been driven by collaboration. Every breakthrough, every clinical trial, and every new treatment is made possible because patients, researchers, clinicians, and organizations come together with a shared purpose: improving the lives of people affected by cancer. That is why we are incredibly honored to be selected as CTI Clinical…
-
MEET YOUR STAFF: Introducing our first Director of Philanthropy, Roberta Plantak
Roberta joined the ALK Positive, Inc. team in March 2026 as our first Director of Philanthropy and has already been making a big difference. We wanted our readers to get to know her more both in her professional capacity, and “behind the scenes”.
-
First Patient Dosed in Tri-611 Clinical Trial
The first patient has been dosed in the Phase 1/2 clinical trial evaluating TRI-611 for ALK-positive NSCLC, marking an important step forward in the development of new investigational therapies for the ALK-positive community.
-
Nuvalent Announces Submission of New Drug Application to the FDA for Neladalkib (NVL-655) in TKI Pre-treated Advanced ALK-positive NSCLC
Nuvalent has officially filed for FDA approval of NVL-655 (neladalkib), a promising next-generation ALK inhibitor for previously treated ALK-positive lung cancer. Backed by results from the ongoing ALKOVE-1 trial, this milestone could bring a powerful new treatment option one step closer for patients facing progression after prior ALK therapies.
-
Honoring a Legacy: The John Pender Scholarship Fund
The John Pender Scholarship Fund, established in 2025, honors John’s legacy by supporting students connected to the ALK-positive community who are pursuing higher education. Each year, the scholarship helps a student working toward a future rooted in service, creativity, innovation, or care for others. The inaugural award supported a student pursuing nursing, continuing John’s spirit…
-
ALK Positive Grants Support Dr. Alice Shaw’s Pioneering ALK-Positive Lung Cancer Research
ALK Positive is proud to support Dr. Alice Shaw’s pre-clinical research advancing the understanding of ALK-positive lung cancer. Her work focuses on uncovering biological mechanisms that drive treatment resistance, with the goal of informing future therapeutic strategies and improving long-term outcomes for patients. Through this partnership, ALK Positive is investing in science that accelerates progress…
-
ALK Positive and Pfizer Announce New Grant Opportunity to Improve Education and Support for People Living With Advanced ALK+ Lung Cancer
We’re proud to partner with Pfizer on a new grant opportunity designed to strengthen education for people diagnosed with advanced ALK-positive lung cancer. This RFP supports independent projects that help patients and care partners prepare for treatment, recognize side effects early, and access clear, inclusive resources that honor their preferences. Funding is available for organizations…
-
ALK Positive and the American Association for Cancer Research (AACR) partner to fund a two-year AACR-ALK Positive Lung Cancer Research Fellowship
ALK Positive Partners with AACR to Advance ALK-Positive Lung Cancer Research ALK Positive has partnered with the American Association for Cancer Research (AACR) to fund a two-year AACR–ALK Positive Lung Cancer Research Fellowship supporting early-career investigators in ALK-positive lung cancer research. The 2025 awardee, Alice Tzeng, MD, PhD of Dana-Farber Cancer Institute, is studying epigenetic…
-
ALK Positive Inc. Appoints Dr. Ken Culver as Executive Director & Medical Director to Lead Research and Patient Advocacy Initiatives
ALK Positive has appointed Dr. Ken Culver as Executive Director and Medical Director to guide the organization’s strategy and research investments. A physician-scientist with expertise in oncology and drug development, Dr. Culver has advanced patient-driven science and global collaborations since joining ALK Positive in 2022. His leadership marks an exciting new chapter in accelerating research…
-
Participate in Survey to Help our Medical Committee
The ALK Positive Inc. Medical Committee is seeking patient and caregiver input to enhance DDI Manager — an online resource that helps identify potential drug–drug interactions between cancer treatments and other medications. Your feedback can make a real difference in improving this tool for the entire ALK+ community. Participation takes just 10–15 minutes.
-
Takeda Oncology Co-Pay Assistance Progam
As of October 1, 2025, ALUNBRIG® (brigatinib) is now covered at Cigna Healthcare, giving most commercial patients faster access and lower out-of-pocket costs. With this update, about 99% of commercial lives are covered for ALUNBRIG. Learn more about co-pay assistance at takedaoncologycopay.com .